Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine
- 128 Downloads
Recently, we reported that compared to haloperidol, chronic exposure to either the risperidone (RISP) or olanzapine (OLZ) resulted in superior effects on spatial learning performance as well as the cholinergic neurons, although the mechanism for these effects was not addressed.
The objective of this study was to investigate one plausible mechanism whereby RISP and OLZ exert superior effects on cholinergic neurons, i.e. positive effects on nerve growth factor (NGF), which is known to regulate the brain cholinergic activity as well as cognitive function. Therefore, the effects of chronic exposure to HAL, RISP, or OLZ on the expression of NGF and choline acetyltransferase (ChAT) in the hippocampus (i.e. a brain area well known to be involved in cognitive function and known to receive major cholinergic projections from the medial septum) were compared.
Rats were treated with HAL (1 or 2 mg/kg per day), RISP (1.25 or 2.5 mg/kg per day), or OLZ (5 or 10 mg/kg per day) for 45 days in drinking water. NGF and ChAT were measured by immunohistochemistry and NGF protein was also measured by an enzyme-linked ImmunoSorbent assay.
Compared to controls, HAL exposure resulted in a marked reduction in NGF immunoreactivity in the hippocampal dentate gyrus (DG), CA1 and CA3 areas. In contrast, RISP did not alter, while OLZ significantly increased levels of NGF. These changes in NGF levels corresponded well with changes in ChAT immunoreactivity in the hippocampus and the medial septum.
These preclinical data, combined with previously published behavioral results, support the premise that OLZ and RISP, in contrast to HAL, preserve cholinergic pathways and cognitive function via superior effects on NGF expression and are thus therapeutically superior for extended use.
KeywordsAntipsychotics Cognition Nerve growth factor Choline acetyltransferase Haloperidol Risperidone Olanzapine Schizophrenia Rat
The authors acknowledge Ms. Karen Ship for proofing this manuscript. This study was financially supported in part by Janssen Pharmaceutica Research Foundation, Eli Lilly and Company, and The National Institute of Mental Health (MH 066233 to A.V.T.).
- Angelucci F, Aloe L, Gruber SHM, Fiore M, Mathe AK (2000) Chronic antipsychotics treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyltransferase in rat brain regions. Int J Neuropsychopharmacol 3:13–25Google Scholar
- Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87–94Google Scholar
- Jeste DV, Lohr JB, Manley M (1992) Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology 106:154–160Google Scholar
- Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotics drugs: a critical analysis. Psychopharmacology 124:2–34Google Scholar
- Mahadik SP, Evans DR, Terry A, Hill WD (2001) Neuroprotective action of atypical antipsychotics in schizophrenia: improved cognitive performance and underlying mechanism of action. Schizophr Res 49:94Google Scholar
- Meltzer HY (1995) Atypical antipsychotics drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: fourth generation of progress. Raven Press New York, pp 1277–1286Google Scholar
- Parikh V, Khan MM, Salat P, Kalla A, Mahadik SP (2003a) Effects of risperidone, olanzapine and clozapine versus. haloperidol on nerve growth factor and cholinergic activity in rat brain. Biol Psychiatry 53:26SGoogle Scholar
- Paxinos G, Watson CR (1998) The rat atlas in stereotaxic coordinates, 4th edn. Academic Press, San Diego, Calif.Google Scholar
- Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38Google Scholar
- Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18:12S–19SGoogle Scholar
- Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583–594Google Scholar
- Tollefson GD (1996) Cognitive functions in schizophrenic patients. J Clin Psychiatry 57 (Suppl II):31–39Google Scholar